The In-Vitro Measure of Cell Avidity Between Tumor-Effector Pairs, Not Affinity, Predicts Optimal Anti-Tumor Response In-Vivo
Time: 12:45 pm
day: Day One
• We present data discussing how increased specific avidity, those TCR’s with strongest antigen binding with the lowest background, correlate with improved TCR function in-vitro and in-vivo
• A novel assay where cross-reactivity between TCRs and target can be quickly quantified
• How avidity has shown a correlation with improved tumor control in in-vivo murine models, being significantly more correlative to in-vivo outcome than either cytotoxicity assays or IFN-g release.